Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Diffuse Large B Cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (832
)
Mantle Cell Lymphoma (101
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
Non-Hodgkin’s Lymphoma (832
)
Mantle Cell Lymphoma (101
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
›
Associations
(295)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab + polatuzumab vedotin
Sensitive: A1 - Approval
rituximab + polatuzumab vedotin
Sensitive
:
A1
rituximab + polatuzumab vedotin
Sensitive: A1 - Approval
rituximab + polatuzumab vedotin
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lenalidomide + tafasitamab
Sensitive: A1 - Approval
lenalidomide + tafasitamab
Sensitive
:
A1
lenalidomide + tafasitamab
Sensitive: A1 - Approval
lenalidomide + tafasitamab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
polatuzumab vedotin
Sensitive: A1 - Approval
polatuzumab vedotin
Sensitive
:
A1
polatuzumab vedotin
Sensitive: A1 - Approval
polatuzumab vedotin
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive: A1 - Approval
loncastuximab tesirine
Sensitive
:
A1
loncastuximab tesirine
Sensitive: A1 - Approval
loncastuximab tesirine
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
selinexor
Sensitive: A1 - Approval
selinexor
Sensitive
:
A1
selinexor
Sensitive: A1 - Approval
selinexor
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab/hyaluronidase
Sensitive: A1 - Approval
rituximab / hyaluronidase
Sensitive
:
A1
rituximab/hyaluronidase
Sensitive: A1 - Approval
rituximab / hyaluronidase
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
brentuximab vedotin
Sensitive: A2 - Guideline
brentuximab vedotin
Sensitive
:
A2
brentuximab vedotin
Sensitive: A2 - Guideline
brentuximab vedotin
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
TNFRSF8 positive
Diffuse Large B Cell Lymphoma
TNFRSF8 positive
Diffuse Large B Cell Lymphoma
brentuximab vedotin
Sensitive: A2 - Guideline
brentuximab vedotin
Sensitive
:
A2
brentuximab vedotin
Sensitive: A2 - Guideline
brentuximab vedotin
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
MINE
Sensitive: A2 - Guideline
MINE
Sensitive
:
A2
MINE
Sensitive: A2 - Guideline
MINE
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
R-GemOx
Sensitive: A2 - Guideline
R-GemOx
Sensitive
:
A2
R-GemOx
Sensitive: A2 - Guideline
R-GemOx
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
GemOx
Sensitive: A2 - Guideline
GemOx
Sensitive
:
A2
GemOx
Sensitive: A2 - Guideline
GemOx
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
ESHAP
Sensitive: A2 - Guideline
ESHAP
Sensitive
:
A2
ESHAP
Sensitive: A2 - Guideline
ESHAP
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
ICE
Sensitive: A2 - Guideline
ICE
Sensitive
:
A2
ICE
Sensitive: A2 - Guideline
ICE
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
RICE
Sensitive: A2 - Guideline
RICE
Sensitive
:
A2
RICE
Sensitive: A2 - Guideline
RICE
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
carboplatin + rituximab + gemcitabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + rituximab + gemcitabine + dexamethasone
Sensitive
:
A2
carboplatin + rituximab + gemcitabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + rituximab + gemcitabine + dexamethasone
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
carboplatin + gemcitabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + gemcitabine + dexamethasone
Sensitive
:
A2
carboplatin + gemcitabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + gemcitabine + dexamethasone
Sensitive
:
A2
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
GDP
Sensitive: A2 - Guideline
GDP
Sensitive
:
A2
GDP
Sensitive: A2 - Guideline
GDP
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
